financetom
Business
financetom
/
Business
/
Citigroup's Target of 10% ROTCE Gain Is 'Quite Achievable,' Bolstering Stock Outlook, BofA Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Citigroup's Target of 10% ROTCE Gain Is 'Quite Achievable,' Bolstering Stock Outlook, BofA Says
Jun 6, 2024 9:25 AM

12:03 PM EDT, 06/06/2024 (MT Newswires) -- Citigroup's ( C ) management target of topping a 10% return on tangible common equity, or ROTCE, is "quite achievable," signaling potential for a 60% share price rally, BofA Securities said Thursday in a report.

"We have generally agreed with CEO Jane Fraser's strategy to de-risk/simplify the bank, make hard investment choices, create a leaner Citigroup ( C )," the report said, ROTCE may reach 10% in fiscal 2026, BofA said

investors' increased confidence in the achievability of management's targets and visibility into the competitive positioning of each of the bank's business segments may drive a rerating to tangible book value, or TBV, at a faster pace, implying 60% upside by 2025, BofA said.

"While execution risk is significant, we see the hiring of senior external talent as a positive, starting with Andy Sieg who is responsible for turning around the deeply unprofitable and balance sheet reliant wealth business," the report said.

"More recently, the announcement of Viswas Raghavan (a well-regarded leader from JPMorgan, started at Citigroup ( C ) earlier this week) as head of the banking business, increases the odds for improved profitability," the report said.

BofA has a buy rating on Citigroup ( C ) and a $75 price target.

Price: 61.74, Change: -0.03, Percent Change: -0.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Huntington Bancshares signs $1.9 billion deal for rival Veritex in Texas push
Huntington Bancshares signs $1.9 billion deal for rival Veritex in Texas push
Jul 14, 2025
July 14 (Reuters) - U.S. regional lender Huntington Bancshares ( HBAN ) will buy Texas-based smaller rival Veritex Holdings ( VBTX ) in a $1.9 billion all-stock deal, as it looks to expand its presence in the state that is fast emerging as a major financial hub. Shares of Columbus, Ohio-based Huntington Bancshares ( HBAN ), a $210 billion asset...
BioSig Technologies Moves Closer to Becoming Fully Regulated Gold-Backed Token Platform in US
BioSig Technologies Moves Closer to Becoming Fully Regulated Gold-Backed Token Platform in US
Jul 14, 2025
09:02 AM EDT, 07/14/2025 (MT Newswires) -- BioSig Technologies ( BSGM ) said Monday it is taking key steps to become one of the first fully regulated platforms for trading gold-backed digital tokens on a major US exchange after its recent merger with Streamex Exchange. The company said Streamex has hired Compliance Exchange Group to help acquire a specific, unnamed...
ViiV expands licence to allow generic HIV treatment production for low-income countries
ViiV expands licence to allow generic HIV treatment production for low-income countries
Jul 14, 2025
LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir. The updated licence, which builds on an earlier agreement covering cabotegravir for HIV prevention, will enable three generic drugmakers to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved